INTRODUCTION
In China, more than 1.6 million people are newly diagnosed with breast cancer and 1.2 million breast cancer deaths are expected to occur among women each year [1] . The American Cancer Society released the 2013 national cancer statistics report that ranked breast cancer as the highest incidence in women (29%) and the second highest death rate [2] .
Paclitaxel (Taxol) is a powerful chemotherapeutic that has been used to treat ovarian, breast, lung, pancreatic, chemoresistance. Paclitaxel resistance is associated with the acquisition of the epithelial-to-mesenchymal transition (EMT) [5] . Classical EMT-related signaling pathways, breast carcinoma [6, 7] .
protein-coupled receptor CXCR4 pathways in liver tumors CXCL12, also known as stromal cell-derived factor-1 in breast cancer and has been correlated with poor has been shown to play a key role in tumor growth, invasion, and angiogenesis [11] [12] [13] [14] . The results of these tumor microenvironment may alter invasive capacity as well as the tumor-associated immune cells that are linked to increased metastasis and poor prognosis [15] . also been studied in breast cancer treatment [16, 17] . High CXCR4 overexpression from breast cancer patients receiving neoadjuvant chemotherapy was predictive of pathway caused chemoresistance, while CXCR2 blockers tumors, particularly against metastasis [19] . An oncolytic virus armed with a CXCR4 antagonist effectively inhibited the development of spontaneous metastasis and increased overall tumor-free survival [20] .
In a previous study, we reported that and invasion in breast cancer cells by reducing the signaling pathway and the subsequent activation of cancer has not been investigated. In the current study, we discussed whether platelet-derived growth factor reversing CXCR4-induced EMT to provide insight chemotherapy for breast cancer.
RESULTS
The overexpression of PDGF and PDGFR were found in PR cells 
DISCUSSION
The EMT is associated with tumorigenesis and metastasis as well as chemoresistance of cancer. Therefore, elucidating the mechanisms that govern the acquisition of EMT would likely be useful for devising targeted therapeutic approaches to overcome or prevent resistance to conventional cancer therapeutics. Paclitaxel promotes the polymerization of tubulin, thereby causing cell death by disrupting the normal microtubule dynamics Recent studies have shown that links between paclitaxel resistance and EMT lead breast cancer patients to develop chemoresistance [29, 30] . In our previous studies, we acquired EMT feature, as described previously [25, 26] , cells.
CXCR4 expression is higher in dedifferentiated cells than in normal cells and independently predicted poor survival in tumors [31] . The activation of molecular progression and is associated with CXCR4 expression.
which is a selective synthetic polypeptide derived from vMIP-II, from interacting with its natural ligand, our previous study achieved the inhibition of primary tumor growth and metastasis [22, 23] . www.impactjournals.com/oncotarget 
